Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Efstathia Kalli, Vlamos Panayiotis
Individualized nutritional treatment with polyphenols has been proposed in the early stages of Alzheimer’s disease. However, it remains unclear at what doses polyphenols and their metabolites enter the brain tissue and whether they can act at sufficient concentrations. The present review provides useful insights into the multiple modes of actions of selected polyphenols as potential therapeutic tools at the pre-clinical stage of Alzheimer’s disease, as well as their ability to cross the blood-brain barrier and their detrimental effects after high dose consumptions. Several studies proposed flavonoids for their potential value in prevention and treatment of neurodegenerative diseases. The scarcity of clinical data though highlights the need for conducting metabolomics studies and well-designed clinical trials. Prolonged clinical trials with bioinformatics tools are needed to fully elucidate both neuroprotective effects and possible risks from polyphenol consumption at concentrated high doses.